https://www.selleckchem.com/pr....oducts/bromodeoxyuri
of synchronous metastases early in the disease course should be weighed against the risk of futile interventions in a disease with already multimetastatic microscopic dissemination. Therefore, attentive treatment sequencing, meticulous appraisal of cancer extension, refinement of post-treatment surveillance, and understanding of tumor biology and kinetics are crucial in the management of oligometastases.Immunotherapy-based combinations have become standard of care in advanced renal cell carcinoma (RCC). Despite the potent
Like
Comment
Share
